LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 71

Search options

  1. Book: Das Kochbuch der Anna Maria Stainer

    Stainer, Anna A

    1789

    1978  

    Size 192 S, Ill
    Publisher Ueberreuter
    Publishing place Wien
    Document type Book
    ISBN 3800031469 ; 9783800031467
    Database Former special subject collection: coastal and deep sea fishing

    More links

    Kategorien

  2. Article ; Online: Response to: are there over 200 distinct types of interstitial lung diseases?

    Amati, Francesco / Stainer, Anna / Aliberti, Stefano

    Respiratory research

    2024  Volume 25, Issue 1, Page(s) 114

    Language English
    Publishing date 2024-03-06
    Publishing country England
    Document type Letter
    ZDB-ID 2041675-1
    ISSN 1465-993X ; 1465-993X
    ISSN (online) 1465-993X
    ISSN 1465-993X
    DOI 10.1186/s12931-024-02751-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Long-Term Outcomes in Severe Community-Acquired Pneumonia.

    Carella, Francesco / Aliberti, Stefano / Stainer, Anna / Voza, Antonio / Blasi, Francesco

    Seminars in respiratory and critical care medicine

    2024  Volume 45, Issue 2, Page(s) 266–273

    Abstract: Community-acquired pneumonia (CAP) is globally one of the major causes of hospitalization and mortality. Severe CAP (sCAP) presents great challenges and need a comprehensive understanding of its long-term outcomes. Cardiovascular events and neurological ... ...

    Abstract Community-acquired pneumonia (CAP) is globally one of the major causes of hospitalization and mortality. Severe CAP (sCAP) presents great challenges and need a comprehensive understanding of its long-term outcomes. Cardiovascular events and neurological impairment, due to persistent inflammation and hypoxemia, contribute to long-term outcomes in CAP, including mortality. Very few data are available in the specific population of sCAP. Multiple studies have reported variable 1-year mortality rates for patients with CAP up to 40.7%, with a clear influence by age, comorbidities, and disease severity. In terms of treatment, the potential protective role of macrolides in reducing mortality emphasizes the importance of appropriate empiric antibiotic therapy. This narrative review explores the growing interest in the literature focusing on the long-term implications of sCAP. Improved understanding of long-term outcomes in sCAP can facilitate targeted interventions and enhance posthospitalization care protocols.
    MeSH term(s) Humans ; Pneumonia/drug therapy ; Community-Acquired Infections/drug therapy ; Hospitalization
    Language English
    Publishing date 2024-02-23
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 1183617-9
    ISSN 1098-9048 ; 1069-3424
    ISSN (online) 1098-9048
    ISSN 1069-3424
    DOI 10.1055/s-0044-1781426
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Long-Term Outcomes in Severe Community-Acquired Pneumonia

    Carella, Francesco / Aliberti, Stefano / Stainer, Anna / Voza, Antonio / Blasi, Francesco

    Seminars in Respiratory and Critical Care Medicine

    (Severe community acquired pneumonia)

    2024  Volume 45, Issue 02, Page(s) 266–273

    Abstract: Community-acquired pneumonia (CAP) is globally one of the major causes of hospitalization and mortality. Severe CAP (sCAP) presents great challenges and need a comprehensive understanding of its long-term outcomes. Cardiovascular events and neurological ... ...

    Series title Severe community acquired pneumonia
    Abstract Community-acquired pneumonia (CAP) is globally one of the major causes of hospitalization and mortality. Severe CAP (sCAP) presents great challenges and need a comprehensive understanding of its long-term outcomes. Cardiovascular events and neurological impairment, due to persistent inflammation and hypoxemia, contribute to long-term outcomes in CAP, including mortality. Very few data are available in the specific population of sCAP. Multiple studies have reported variable 1-year mortality rates for patients with CAP up to 40.7%, with a clear influence by age, comorbidities, and disease severity. In terms of treatment, the potential protective role of macrolides in reducing mortality emphasizes the importance of appropriate empiric antibiotic therapy. This narrative review explores the growing interest in the literature focusing on the long-term implications of sCAP. Improved understanding of long-term outcomes in sCAP can facilitate targeted interventions and enhance posthospitalization care protocols.
    Keywords severe community-acquired pneumonia ; long-term outcomes ; long-term mortality ; narrative review
    Language English
    Publishing date 2024-02-23
    Publisher Thieme Medical Publishers, Inc.
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 1183617-9
    ISSN 1098-9048 ; 1069-3424
    ISSN (online) 1098-9048
    ISSN 1069-3424
    DOI 10.1055/s-0044-1781426
    Database Thieme publisher's database

    More links

    Kategorien

  5. Article ; Online: Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review.

    Amati, Francesco / Stainer, Anna / Polelli, Veronica / Mantero, Marco / Gramegna, Andrea / Blasi, Francesco / Aliberti, Stefano

    International journal of molecular sciences

    2023  Volume 24, Issue 9

    Abstract: Pirfenidone and nintedanib are antifibrotic medications approved for idiopathic pulmonary fibrosis treatment by regulatory agencies and available for clinical use worldwide. These drugs have been shown to reduce the rate of decline in forced vital ... ...

    Abstract Pirfenidone and nintedanib are antifibrotic medications approved for idiopathic pulmonary fibrosis treatment by regulatory agencies and available for clinical use worldwide. These drugs have been shown to reduce the rate of decline in forced vital capacity and the risk of acute exacerbation among patients with idiopathic pulmonary fibrosis. Recent data suggest that different interstitial lung diseases with a progressive pulmonary fibrosis phenotype can share similar pathogenetic and biological pathways and could be amenable to antifibrotic therapies. Indeed, historical management strategies in interstitial lung disease have failed to identify potential treatments once progression has occurred despite available drugs. In this systematic review, we summarized data on the efficacy of pirfenidone and nintedanib in interstitial lung diseases other than idiopathic pulmonary fibrosis as well as ongoing and upcoming clinical trials. We identify two well-designed trials regarding nintedanib demonstrating the efficacy of this drug in slowing disease progression in patients with interstitial lung diseases other than idiopathic pulmonary fibrosis. On the other hand, results on the use of pirfenidone in interstitial lung diseases other than idiopathic pulmonary fibrosis should be interpreted with more caution on the basis of trial limitations. Several randomized control trials are underway to improve the quality of evidence in the interstitial lung disease field.
    MeSH term(s) Humans ; Idiopathic Pulmonary Fibrosis/drug therapy ; Idiopathic Pulmonary Fibrosis/pathology ; Lung Diseases, Interstitial/drug therapy ; Indoles/therapeutic use ; Pyridones/therapeutic use ; Treatment Outcome
    Chemical Substances nintedanib (G6HRD2P839) ; pirfenidone (D7NLD2JX7U) ; Indoles ; Pyridones
    Language English
    Publishing date 2023-04-25
    Publishing country Switzerland
    Document type Systematic Review ; Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms24097849
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Cardiovascular Complications in Community-Acquired Pneumonia.

    Desai, Antonio / Aliberti, Stefano / Amati, Francesco / Stainer, Anna / Voza, Antonio

    Microorganisms

    2022  Volume 10, Issue 11

    Abstract: Community-acquired pneumonia (CAP) is accountable for high mortality in both pediatric and adult populations worldwide, about one-third of hospitalized patients pass away within a year of being discharged from the facility. The high mortality and ... ...

    Abstract Community-acquired pneumonia (CAP) is accountable for high mortality in both pediatric and adult populations worldwide, about one-third of hospitalized patients pass away within a year of being discharged from the facility. The high mortality and morbidity rates are closely related to cardiovascular complications that are consequent or concomitant to the acute episode of pneumonia. An updated perspective on the major pathophysiological mechanisms, prevalence, risk factors, outcomes, and relevant treatments of cardiovascular events in CAP patients is provided in the current study. It is possible to evaluate the pathophysiology of cardiac disease in this population based on plaque-related events, such as acute myocardial infarction, or events unrelated to plaque, such as arrhythmias and heart failure. With an absolute rate of cardiovascular problems ranging broadly from 10% to 30%, CAP raises the risk of both plaque-related and plaque-unrelated events. Both in- and out-patients may experience these issues at admission, throughout hospitalization, or even up to a year following discharge. At long-term follow-up, cardiac events account for more than 30% of deaths in CAP patients, making them a significant cause of mortality. If patients at risk for cardiac events are stratified, diagnostic tools, monitoring, and preventive measures may be applied to these patients. A prospective evaluation of cardioprotective treatments is urgently required from a research point of view.
    Language English
    Publishing date 2022-11-02
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2720891-6
    ISSN 2076-2607
    ISSN 2076-2607
    DOI 10.3390/microorganisms10112177
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Identify Drug-Resistant Pathogens in Patients with Community-Acquired Pneumonia.

    Amati, Francesco / Bindo, Francesco / Stainer, Anna / Gramegna, Andrea / Mantero, Marco / Nigro, Mattia / Bussini, Linda / Bartoletti, Michele / Blasi, Francesco / Aliberti, Stefano

    Advances in respiratory medicine

    2023  Volume 91, Issue 3, Page(s) 224–238

    Abstract: A substantial increase in broad-spectrum antibiotics as empirical therapy in patients with community-acquired pneumonia (CAP) has occurred over the last 15 years. One of the driving factors leading to that has been some evidence showing an increased ... ...

    Abstract A substantial increase in broad-spectrum antibiotics as empirical therapy in patients with community-acquired pneumonia (CAP) has occurred over the last 15 years. One of the driving factors leading to that has been some evidence showing an increased incidence of drug-resistant pathogens (DRP) in patients from a community with pneumonia, including methicillin-resistant
    MeSH term(s) Humans ; Methicillin-Resistant Staphylococcus aureus ; Community-Acquired Infections/drug therapy ; Pneumonia/drug therapy ; Pneumonia/epidemiology ; Anti-Bacterial Agents/therapeutic use
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2023-05-31
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2893877-X
    ISSN 2543-6031 ; 2451-4934
    ISSN (online) 2543-6031
    ISSN 2451-4934
    DOI 10.3390/arm91030018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Cardiovascular Complications in Community-Acquired Pneumonia

    Antonio Desai / Stefano Aliberti / Francesco Amati / Anna Stainer / Antonio Voza

    Microorganisms, Vol 10, Iss 2177, p

    2022  Volume 2177

    Abstract: Community-acquired pneumonia (CAP) is accountable for high mortality in both pediatric and adult populations worldwide, about one-third of hospitalized patients pass away within a year of being discharged from the facility. The high mortality and ... ...

    Abstract Community-acquired pneumonia (CAP) is accountable for high mortality in both pediatric and adult populations worldwide, about one-third of hospitalized patients pass away within a year of being discharged from the facility. The high mortality and morbidity rates are closely related to cardiovascular complications that are consequent or concomitant to the acute episode of pneumonia. An updated perspective on the major pathophysiological mechanisms, prevalence, risk factors, outcomes, and relevant treatments of cardiovascular events in CAP patients is provided in the current study. It is possible to evaluate the pathophysiology of cardiac disease in this population based on plaque-related events, such as acute myocardial infarction, or events unrelated to plaque, such as arrhythmias and heart failure. With an absolute rate of cardiovascular problems ranging broadly from 10% to 30%, CAP raises the risk of both plaque-related and plaque-unrelated events. Both in- and out-patients may experience these issues at admission, throughout hospitalization, or even up to a year following discharge. At long-term follow-up, cardiac events account for more than 30% of deaths in CAP patients, making them a significant cause of mortality. If patients at risk for cardiac events are stratified, diagnostic tools, monitoring, and preventive measures may be applied to these patients. A prospective evaluation of cardioprotective treatments is urgently required from a research point of view.
    Keywords acute myocardial infarction ; arrhythmia ; cardiovascular complications ; community-acquired pneumonia ; heart failure ; stroke ; Biology (General) ; QH301-705.5
    Subject code 610
    Language English
    Publishing date 2022-11-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article ; Online: Treatable Traits in Systemic Sclerosis.

    Amati, Francesco / Bongiovanni, Gabriele / Tonutti, Antonio / Motta, Francesca / Stainer, Anna / Mangiameli, Giuseppe / Aliberti, Stefano / Selmi, Carlo / De Santis, Maria

    Clinical reviews in allergy & immunology

    2023  Volume 65, Issue 2, Page(s) 251–276

    Abstract: Systemic sclerosis (SSc) is a chronic systemic disease within the spectrum of connective tissue diseases, specifically characterized by vascular abnormalities and inflammatory and fibrotic involvement of the skin and internal organs resulting in high ... ...

    Abstract Systemic sclerosis (SSc) is a chronic systemic disease within the spectrum of connective tissue diseases, specifically characterized by vascular abnormalities and inflammatory and fibrotic involvement of the skin and internal organs resulting in high morbidity and mortality. The clinical phenotype of SSc is heterogeneous, and serum autoantibodies together with the extent of skin involvement have a predictive value in the risk stratification. Current recommendations include an organ-based management according to the predominant involvement with only limited individual factors included in the treatment algorithm. Similar to what has been proposed for other chronic diseases, we hypothesize that a "treatable trait" approach based on relevant phenotypes and endotypes could address the unmet needs in SSc stratification and treatment to maximize the outcomes. We provide herein a comprehensive review and a critical discussion of the literature regarding potential treatable traits in SSc, focusing on established and candidate biomarkers, with the purpose of setting the bases for a precision medicine-based approach. The discussion, structured based on the organ involvement, allows to conjugate the pathogenetic mechanisms of tissue injury with the proposed predictors, particularly autoantibodies and other serum biomarkers. Ultimately, we are convinced that precision medicine is the ideal guide to manage a complex condition such as SSc for which available treatments are largely unsatisfactory.
    Language English
    Publishing date 2023-08-21
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1239045-8
    ISSN 1559-0267 ; 1080-0549
    ISSN (online) 1559-0267
    ISSN 1080-0549
    DOI 10.1007/s12016-023-08969-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Vasoactive drugs for the treatment of pulmonary hypertension associated with interstitial lung diseases: a systematic review.

    Bongiovanni, Gabriele / Tonutti, Antonio / Stainer, Anna / Nigro, Mattia / Kellogg, Dean L / Nambiar, Anoop / Gramegna, Andrea / Mantero, Marco / Voza, Antonio / Blasi, Francesco / Aliberti, Stefano / Amati, Francesco

    BMJ open respiratory research

    2024  Volume 11, Issue 1

    Abstract: Objectives: Vasoactive drugs have exhibited clinical efficacy in addressing pulmonary arterial hypertension, manifesting a significant reduction in morbidity and mortality. Pulmonary hypertension may complicate advanced interstitial lung disease (PH-ILD) ...

    Abstract Objectives: Vasoactive drugs have exhibited clinical efficacy in addressing pulmonary arterial hypertension, manifesting a significant reduction in morbidity and mortality. Pulmonary hypertension may complicate advanced interstitial lung disease (PH-ILD) and is associated with high rates of disability, hospitalisation due to cardiac and respiratory illnesses, and mortality. Prior management hinged on treating the underlying lung disease and comorbidities. However, the INCREASE trial of inhaled treprostinil in PH-ILD has demonstrated that PH-ILD can be effectively treated with vasoactive drugs.
    Methods: This comprehensive systematic review examines the evidence for vasoactive drugs in the management of PH-ILD.
    Results: A total of 1442 pubblications were screened, 11 RCTs were considered for quantitative synthesis. Unfortunately, the salient studies are limited by population heterogeneity, short-term follow-up and the selection of outcomes with uncertain clinical significance.
    Conclusions: This systematic review underscores the necessity of establishing a precision medicine-oriented strategy, directed at uncovering and addressing the intricate cellular and molecular mechanisms that underlie the pathophysiology of PH-ILD.
    Prospero registration number: CRD42023457482.
    MeSH term(s) Humans ; Hypertension, Pulmonary/drug therapy ; Hypertension, Pulmonary/etiology ; Lung Diseases, Interstitial/complications ; Lung Diseases, Interstitial/drug therapy ; Lung Diseases, Interstitial/epidemiology ; Comorbidity
    Language English
    Publishing date 2024-03-13
    Publishing country England
    Document type Systematic Review ; Journal Article
    ZDB-ID 2736454-9
    ISSN 2052-4439 ; 2052-4439
    ISSN (online) 2052-4439
    ISSN 2052-4439
    DOI 10.1136/bmjresp-2023-002161
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top